On June 2, 2020, the AAPS filed a complaint in federal court seeking declaratory and injunctive relief to compel the Food & Drug Administration (FDA), the Biomedical Advanced Research & Development Authority (BARDA), and the Department of Health & Human Services (HHS) to release from the Strategic National Stockpile (SNS) approximately 150 million doses of hydroxychloroquine (HCQ) for use by prescribing physicians....
...The AAPS’s complaint alleges that “through a biased, unlawful process,” FDA officials from “prior administrations” and “contrary to the wishes of President Donald Trump” arbitrarily limited the use of HCQ from the SNS. The complaint specifically references, among others, Rick Bright, the director of the Biomedical Advanced Research & Development Authority (BARDA).......in a reference to the experimental drug remdesivir, the complaint states that “Bright favors an expensive, proprietary antiviral medication developed by Gilead Sciences” based on a “pre-conceived opinion in favor of Gilead which should have caused his recusal from the decision-making process about HCQ.”Based on a whistleblower complaint by Bright against the Trump administration, the AAPS avers that Janet Woodcock, the director of the FDA’s Center for Drug Evaluation and Research, “also played a pivotal role in pushing for the EUA.” The AAPS complaint alleges that “Woodcock also occupied a top position in a public-private operation designed to approve new vaccines for COVID-19, and she reportedly communicated with a Wall Street analyst concerning such development.”
Here it comes—the cure and the vaccine/prophylactic! No more excuses, sheeples!
ReplyDelete